Abbott’s cancer deal just shaved its profit outlook

The diagnosis: a smaller profit outlook

Abbott Laboratories just took a little scissors to its 2026 earnings forecast. The company now expects adjusted profit of $5.38 to $5.58 a share, down from its earlier $5.55 to $5.80 range, after accounting for the impact of last year’s $21 billion cancer-screening deal.

Why the market flinched

This isn’t exactly the kind of “strategic adjustment” that gets applause at the office. The deal was supposed to juice Abbott’s diagnostics business, but in the short term it’s also pressuring profitability — which is why the shares slipped after the update.

The silver lining, because there is one

Abbott did keep its growth story intact. The company still expects 2026 comparable sales growth of 6.5% to 7.5%, which tells you demand isn’t falling off a cliff. The issue is more about how much of that growth drops to the bottom line.

Big picture

For investors, this is the classic trade-off: buy the growth engine now, swallow the margin pain later. Abbott still looks like it’s trying to reboot its diagnostics business, but the market is clearly asking, “Cool — when does the payoff show up?”